Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Champions Oncology (CSBR) Equity Average (2016 - 2026)

Champions Oncology has reported Equity Average over the past 16 years, most recently at $4.3 million for Q1 2026.

  • For Q1 2026, Equity Average rose 38.44% year-over-year to $4.3 million; the TTM value through Jan 2026 reached $4.3 million, up 38.44%, while the annual FY2025 figure was $934500.0, 31.61% down from the prior year.
  • Equity Average for Q1 2026 was $4.3 million at Champions Oncology, up from $3.9 million in the prior quarter.
  • Over five years, Equity Average peaked at $9.2 million in Q2 2022 and troughed at -$2.0 million in Q2 2024.
  • A 5-year average of $4.1 million and a median of $3.9 million in 2025 define the central range for Equity Average.
  • Biggest five-year swings in Equity Average: tumbled 134.18% in 2024 and later soared 2126.07% in 2025.
  • Year by year, Equity Average stood at $9.1 million in 2022, then crashed by 89.01% to $998000.0 in 2023, then crashed by 82.52% to $174500.0 in 2024, then soared by 2126.07% to $3.9 million in 2025, then grew by 9.59% to $4.3 million in 2026.
  • Business Quant data shows Equity Average for CSBR at $4.3 million in Q1 2026, $3.9 million in Q4 2025, and $3.7 million in Q3 2025.